Active, not recruitingPhase 3NCT04849741
A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)
Studying Alexander disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Intervention
- zilganersen(drug)
- Enrollment
- 54 enrolled
- Eligibility
- 2-65 years · All sexes
- Timeline
- 2021 – 2029
Study locations (13)
- Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
- Children's Hospital of Atlanta, Atlanta, Georgia, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Murdoch Children's Research Institute, Parkville, Victoria, Australia
- McGill University Health Centre, Montreal, Quebec, Canada
- Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Ospedale dei Bambini Vittore Buzzi, Milan, Italy
- Ospedale Pediatrico Bambino Gesù, Roma, Italy
- National Center of Neurology and Psychiatry, Tokyo, Kodaira-shi, Japan
- Amsterdam Universitair Medische Centra - Academisch Medisch Centrum, Amsterdam, North Holland, Netherlands
- University College London Hospitals NHS Foundation Trust, London, United Kingdom
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04849741 on ClinicalTrials.govOther trials for Alexander disease
Additional recruiting or active studies for the same condition.